| __timestamp | Madrigal Pharmaceuticals, Inc. | Novo Nordisk A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 15746000 | 26760000000 |
| Thursday, January 1, 2015 | 13392000 | 32169000000 |
| Friday, January 1, 2016 | 9290000 | 32339000000 |
| Sunday, January 1, 2017 | 7672000 | 32124000000 |
| Monday, January 1, 2018 | 15293000 | 33313000000 |
| Tuesday, January 1, 2019 | 22648000 | 35830000000 |
| Wednesday, January 1, 2020 | 21864000 | 36886000000 |
| Friday, January 1, 2021 | 37318000 | 41058000000 |
| Saturday, January 1, 2022 | 48130000 | 50684000000 |
| Sunday, January 1, 2023 | 108146000 | 61598000000 |
| Monday, January 1, 2024 | 67377000000 |
Data in motion
In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. Novo Nordisk A/S and Madrigal Pharmaceuticals, Inc. offer a fascinating study in contrasts. Over the past decade, Novo Nordisk has consistently maintained a robust SG&A expense, peaking at approximately $61.6 billion in 2023, reflecting its expansive global operations. In contrast, Madrigal Pharmaceuticals, with a more focused portfolio, saw its SG&A expenses grow from $15.7 million in 2014 to $108 million in 2023, marking a staggering 587% increase. This growth underscores Madrigal's aggressive market expansion and investment in sales and administrative capabilities. While Novo Nordisk's expenses grew by about 130% over the same period, its scale and market presence provide a different efficiency narrative. This comparison highlights the diverse strategies companies employ to balance growth and operational costs in the pharmaceutical sector.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Amgen Inc.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or Catalent, Inc.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Cytokinetics, Incorporated
Novo Nordisk A/S or Verona Pharma plc: Who Manages SG&A Costs Better?
Novo Nordisk A/S and Ionis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or ADMA Biologics, Inc.
Comparing SG&A Expenses: Novo Nordisk A/S vs Amneal Pharmaceuticals, Inc. Trends and Insights
Novo Nordisk A/S and Vericel Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Madrigal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Madrigal Pharmaceuticals, Inc. and CRISPR Therapeutics AG
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Veracyte, Inc. Trends and Insights
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs HUTCHMED (China) Limited Trends and Insights